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Homology modellingGM1 gangliosidosis and Morquio B syndrome, both arising from beta-galactosidase (GLB1) deﬁciency, are very
rare lysosomal storage diseases with an incidence of about 1:100,000–1:200,000 live births worldwide. Here we
report the beta-galactosidase gene (GLB1) mutation analysis of 21 unrelated GM1 gangliosidosis patients, and of
4 Morquio B patients, of whom two are brothers. Clinical features of the patients were collected and compared
with those in literature. In silico analyses were performed by standard alignments tools and by an improved
version of GLB1 three-dimensional models. The analysed cohort includes remarkable cases. One patient with
GM1 gangliosidosis had a triple X syndrome. One patient with juvenile GM1 gangliosidosis was homozygous
for a mutation previously identiﬁed in Morquio type B. A patient with infantile GM1 gangliosidosis carried a
complex GLB1 allele harbouring two genetic variants leading to p.R68W and p.R109W amino acid changes, in
trans with the known p.R148C mutation. Molecular analysis showed 27 mutations, 9 of which are new: 5
missense, 3 microdeletions and a nonsense mutation. We also identiﬁed four new genetic variants with a
predicted polymorphic nature that was further investigated by in silico analyses. Three-dimensional structural
analysis of GLB1 homologymodels including the newmissensemutations and the p.R68W and p.R109W amino
acid changes showed that all the amino acid replacements affected the resulting protein structures in different
ways, from changes in polarity to folding alterations. Genetic and clinical associations led us to undertake a
critical review of the classiﬁcations of late-onset GM1 gangliosidosis and Morquio B disease.iglustat Zavesca, N-butyldeoxynojirimycin; EBP, elastin
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e).
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783A. Caciotti et al. / Biochimica et Biophysica Acta 1812 (2011) 782–7901. IntroductionGM1 gangliosidosis and Morquio B are autosomal recessive storage
disorders caused by the deﬁciency of β-galactosidase (GLB1), a lyso-
somal hydrolase that may be defective with respect to gangliosides,
lactosylceramide, asialofetuin, oligosaccharides carrying terminal β-
linked galactose and keratan sulfate (in GM1 gangliosidosis) and to
keratan sulfate alone (in Morquio B disease) [1,2].
GM1 gangliosidosis is a neurodegenerative condition for which
three main clinical forms have been identiﬁed: type I (infantile),
type II (late infantile/juvenile), and type III (adult) [1]. The severe
infantile phenotype (type I) is characterised by psychomotor
regression by the age of 6 months, visceromegaly, cherry red
spot, and facial and skeletal abnormalities [1]. The type II form
usually starts between 7 months and 3 years of age with slowly
progressive neurological signs including early locomotor problems,
strabismus, muscle weakness, seizures, lethargy, and terminal
bronchopneumonia [1]. Dysmorphisms and skeletal changes are
less severe than seen in type I. The adult form (type III), the
mildest phenotype of the disease, with onset between 3 and
30 years, is characterised by cerebellar dysfunction, dystonia,
slurred speech, short stature and mild vertebral deformities [1].
The estimated incidence of GM1 gangliosidosis is 1:100,000–
200,000 live births [3].
Morquio B disease is a mucopolysaccharidosis (also called MPS IVB)
characterised by typical and massive skeletal changes, corneal clouding
and impaired cardiac function. A primary central nervous system
involvement is not proven [1]. The estimated incidence of Morquio B
covers a wide range, from 1 case per 75,000 births in Northern Ireland
[4], to 1 case per 640,000 in Western Australia [5].
A problematic partition between Morquio B and juvenile GM1
gangliosidosis phenotypes has been discussed [2]. An intermediate
phenotype between GM1 gangliosidosis and Morquio B disease was
also recently proposed in a patient homozygous for the p.R333H
mutation [6]. Likewise, a patient with an intermediate phenotype
between infantile and juvenile GM1 gangliosidosis has been
reported and associated with a complex allele carrying the common
p.R201H amino acid substitution in cis with the p.L436F polymor-
phism [7].
At present only symptomatic treatments are available for GM1
gangliosidosis or Morquio B diseases. Substrate reduction therapy
mediated by N-butyldeoxynojirimycin (NB-DNJ, Miglustat) has been
used with encouraging results for the treatment of patients with
mild to moderate type 1 Gaucher disease, Niemann–Pick disease
type C and chronic GM2 gangliosidosis type Sandhoff [8–11]. Inter-
esting results have also been reported in a mouse model of GM1
gangliosidosis [12].
The GLB1 protein is encoded by the GLB1 gene (E.C.3.2.1.23; MIM
230500), mapping on the 3p21.33 chromosome. It gives rise to two
alternately spliced mRNAs: a transcript of 2.5 kb, encoding the
lysosomal enzyme, and a transcript of 2.0 kb encoding the elastin
binding protein (EBP), which is located in the endosomal compart-
ment [13,14]. It has been demonstrated that a depletion of EBP in
arterial smooth muscle, ﬁbroblasts and chondroblasts interferes with
elastic-ﬁber assembly [15,16].
To date more than 130 genetic lesions have been described [3,17].
The tertiary structure of human GLB1 has not been resolved, although
the Glu268 and the Asp332 residues, conserved between species,
appear to be part of the catalytic sites [18–20]. A previous homology
model of human GLB1 was derived from the structure of the
Bacteroides thetaiotaomicron GLB1 protein [21].
Here we report the molecular analysis of 21 GM1 gangliosidosis
patients and 4 Morquio B patients, as well as the in silico and structural
characterisation of the new amino acid variants identiﬁed, including
mutations and polymorphisms. Our purpose for undertaking this study
was to clarify the role of the mutated alleles in determining patients’phenotypes and improve the molecular diagnostic yield in differenti-
ating GM1 forms and/or Morquio B disease.
2. Materials and methods
2.1. Patients
2.1.1. GM1 gangliosidosis patients
The main clinical features are summarised in Table 1, parts I and II
(GM1 gangliosidosis), and in Table 2 (Morquio B).
The GM1 gangliosidosis patients here reported are affected by
infantile or juvenile forms. Clinical assessment of this cohort uncovers
three remarkable cases who are described in detail below.
2.1.2. Patient 1 (see Table 1, Part I)
This patient is the second child of unrelated parents; the brother
is healthy but the patient's mother showed a history of multiple
miscarriages (four foetuses in the ﬁrst trimester and two during
the second trimester of pregnancy). Karyotyping on parents and on
one of the miscarried foetuses resulted normal. The patient's father
is of Irish/Italian descent and the maternal branch is Irish/
Scandinavian.
The patient presented at 4 months with oedema in the limbs and
increased alkaline phosphatase, referred as the result of a clavicle
fracture at birth. No cardiac dysfunction or structural abnormalities as
cardiomyopathy or valve defects were found at this period and in the
further examinations. X-ray showed some demineralization of the
bone and early rachitic changes. Psychomotor and relational devel-
opment and feeding skills were referred as normal until 1 year of age,
although mild coarseness of the face and slight hepatosplenomegaly
were observed. At 1 year and 4 months the main clinical ﬁndings
included moderately severe hearing loss, bilateral inguinal hernia,
marked macrocephaly and plagiocephaly, axial hypotonia, and
suspected gelastic seizures due to recurrent laughing spells. Gastro-
stomy tube was introduced due to gastroesophageal reﬂux, on one
occasion complicated by pneumonia. Bone MRI showed gibbous
deformity and scoliosis, and brain MRI revealed diffuse dysmyelina-
tion. The patient was treated brieﬂy with Miglustat. However due to
the severe progressive neurological involvement as well as diarrhoea
and weight loss, the treatment was discontinued.
2.1.3. Patient 15 (see Table 1, Part II)
The patient is a 3-year,6-month-old female who presented with
psychomotor regression at 1 year of age. At 16 months she exhibited
limb hypotonia and mild psychomotor delay. The biochemical GLB1
enzyme activity measured in cultured ﬁbroblasts was 15 nmol/mg/h
(n.v. 400–1100), thus resulting in about 2% of control GLB1 activity.
She also had a 47, XXX karyotype, and brain MRI revealed aspeciﬁc
white matter alterations (particularly periventricular). At present,
delayed development of motor skills, hypotonia, behavioral and
emotional difﬁculties, likely associated with triple X syndrome, were
masked by GM1 gangliosidosis phenotype. Otherwise it should be
considered that the patient could have not developed any symptoms
given her young age.
Due to the age of onset of clinical manifestation the patient was
diagnosed with late-infantile/juvenile GM1 gangliosidosis. However,
the course of the disease was relatively rapid according to the
detection of very low residual GLB1 enzyme activity (about 2% of
control values) with psychomotor regression and loss of motor
abilities. Currently she also presents severe dysphagia, quadriparesis,
frequent respiratory infections and focal seizures.
2.1.4. Patient 20 (see Table 1, Part II)
The patient is the second-born female of consanguineous Roma-
nian parents. She had a normal psychomotor development until the
age of 2 years when she presented with an episode of diarrhoea and
Table 1
Main clinical and instrumental data of GM1 gangliosidosis patients here reported.
Part I
Patient 1 2 3 4 5
Ethnic origin Caucasian Caucasian Caucasian Caucasian Caucasian
Phenotype I I I I I
Sex M M F M F
Onset 4 m 4 m Neonatal Fetal 3 m
Presentation Edema Hypotonia − Hydrops fetalis Oedema, failure to thrive,
psychomotor delay
Age at diagnosis 10 m 7 m Neonatal 2 m 30 m
Psychomotor delay Mild No active posturing − + +
Nervous and muscle systems Hypotonia, gelastic
seizures
− − Hypotonia,
spasticity
Encephalopathy,
tetraparesis,
hypotonia, seizures,
myoclonic jerks
Coarse facies Mild + − + +
Eyes − No − c.r.s c.r.s, v.l
Spleen/liver megaly Mild + − + +
Cardio myopathy No No − + +
Respiratory involvement + No − + +
Brain MRI Dys − − − Dys
GLB1 (% of control activity *) 1.1 FB Absent Absent Absent Absent
Other Gibbous, scoliosis, bone
demineralization, PEG
(14 m), macrocephaly
− − + Dysostosis multiplex,
PEG (16 m),
macrocephaly
Exitus Alive (16 m) 22 m 2 m 26 m 35 m
Legend: I=infantile; J=juvenile; A=adult; +=presence of the symptom; −=not available data; no=normal; y=years; m=months. FB=on ﬁbroblasts; L=on leukocytes;
S=on serum. PFO=patent foramen ovale; RBBB=right bundle branch block; PEG=percutaneous endoscopic gastrostomy; w.m=white matter; t.c.c=thin corpus callosum;
Dys=dysmileinisation; SD=standard deviation; c.r.s=cherry red spot; v.l.=visual loss; o.a.=optic atrophy.
⁎ Standard deviations generate conﬁdence limits less than 1% for all value.
Part II
Patient 11 12 13 14 15
Ethnic origin Indian Caucasian Caucasian Sri Lanka Caucasian
Phenotype I I I I I/J
Sex F M M F F
Onset 3 m Neonatal Neonatal 2 m 1 y
Presentation PFO Hypotonia, respiratory
insufﬁciency, PFO
Hypotonia, deafness,
psychomotor delay, hydrocele
Psychomotor
delay, hypotonia
Psychomotor
regression
Age at diagnosis 14 m 9 m 8 m 14 m 16 m
Psychomotor delay + + + + +
Nervous and muscle systems Hypotonia, myoclonic
seizures
Hypotonia, seizures Axial hypotonia,
tetraparesis,
myoclonic seizures
Tetraparesis, drug-
resistant epilepsy,
dysphagia, dystonia
Tetraparesis,
hypotonia, focal
seizures
Coarse facies + Mild No + −
Eyes c.r.s, o.a v.l c.r.s c.r.s No
Spleen/liver megaly + + + + −
Cardio myopathy No No + +, aortic valve insufﬁciency −
Respiratory involvement + + + + +
Brain MRI Altered signal
intensity of putamen
Supra and sub tentorial
w.m hyperintensity,
t.c.c
w.m and basal ganglia
altered signals,
hydrocephalus, t.c.c
− Aspeciﬁc w.m
alterations
GLB1 (% of control activity)⁎ Absent Absent 1.7 L Absent 2 FB
Other − Macrocephaly Macrocephaly PEG (10 m), umbilical hernia,
microcephaly
Dysphagia
Exitus 20 m Alive (13 m) 17 m 2 y Alive (3 ½y)
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motor abilities andwas clinically stable for several years but at the age
of 12 years athetoid dyskinetic movements appeared. Physical
examination showed grimaces, dystonic movements in the extremi-
ties, dysarthria and ataxia. Mild facial dysmorphism, short-trunk
dwarﬁsm, and sternal protrusionwere also present. GLB1measured on
leukocytes was 5.5 nM/mg/h (n.v. 90–250) and she was given the
diagnosis of juvenile GM1 gangliosidosis. Since the age of 12 years and
6 months, after the ReviewBoard approval, she started treatmentwith
Miglustat with a dosage of 100 mg three times a day. After few weeks,
due to persistent diarrhoea, the dosage was changed to 100 mg two
times a day. After 11 months, on her parents’ initiative, the treatment
was discontinued for 3 months. Then a maintenance treatment with
100 mg three times a day was reintroduced and it is well tolerated. At
present, the patient is 14 years and 6 months old and, despite
treatment, clinical worsening has ensued with anarthria, spasticity
and loss of autonomous walking.2.2. Laboratory and biochemical assays
Human skin ﬁbroblasts from the patients were cultured in
Dulbecco's modiﬁed Eagles–Hams F10 medium (1:1 vol/vol) with
foetal bovine serum (10%) and antibiotics. The Micro BCA protein
Assay kit (Pierce Rockford, USA) was used to set up the starting
proteins used in each enzyme assay. GLB1 and NEU1 activities were
measured in cell lysates of ﬁbroblasts and leukocytes using commercially
available ﬂuorogenic substrates (Moscerdam substrates, Netherlands)
and according to manufacturer's instructions (www.moscerdam.com).
For NEU1 assays: cells lysates, BCA measurements and assays were
performed in fresh samples, lysed by pipetting.
2.3. Genomic DNA analyses and informed consents
Genomic DNA was obtained from patients’ lymphocytes and/or
ﬁbroblasts using a commercial DNA extraction kit (Qiagen, Hilden,
Table 1
Main clinical and instrumental data of GM1 gangliosidosis patients here reported.
Part I
6 7 8 9 10
Indian Romanian Turkish Lybian Caucasian
I I I I I
F M F M F
Fetal 4 m 5 m 5 m 2 m
Microcephaly,
cardiomegaly
Psychomotor delay,
hypotonia
Psychomotor delay Pneumonia, respiratory
insufﬁciency
Psychomotor delay,
hypotonia
19 m 7 m 8 m 6 m 9 m
+ + + + +
Hypotonia, seizures,
myoclonic jerks
Hypotonia Hypotonia − Tetraparesis, drug-resistant
epilepsy, dysphagia
No + + No +
Nystagmus c.r.s c.r.s c.r.s c.r.s
+ + + Mild −
+ No + RBBB No
+ + − + +
t.c.c (13 m) Supra and sub tentorial
w.m hyperintensity
Hemispheric and
cerebellar w.m
hyperintensity
− Basal ganglia, thalami
and w.m hyperintensity
Absent Absent 0.4 S Absent 0.5 L
Absence of type 2A,
atrophy of type 2B
and 2 C ﬁbers
Umbilical hernia,
vertebral hypoplasia
Dysostosis multiplex,
J type sella
− −
19 m 20 m Alive (7 m) − 17 m
Part II
16 17 18 19 20 21
Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian
J J J J J J
F F F M F F
5 y 1 y 5 y 4 y 2 y 4 y
Speech impairment Psychomotor delay,
hypotonia
Psychomotor regression Speech impairment Choreic dystonic
movements, dysarthria
Dysarthria, tremors,
ataxia
10 y 3 y 10 y 11 y 11 y 9 y
Mild + + + No Borderline IQ
Dysarthria Dysarthria, dystonia Motor regression Dysarthria, dystonia
Parkinsonism
Spastic tetraparesis,
dystonia
Dystonia, stiffness
+ No No + Long philtrum Long philtrum
No No No Corneal dystrophy No No
− No No − No No
No No No − No No
− No No − No No
t.c.c, mild cerebral and
cerebellar atrophy, Dys
Brain atrophy − Cerebral and cerebellar
atrophy, basal ganglia
altered signal, Dys
Basal ganglia altered
signal
−
3 L 20 FB Absent 2.3 L 3.6 L; 18.4 FB 2 L; 7.5 FB
− Flattened vertebral
bodies/hook shaped
deformities
Progressive dysostosis
multiplex
Flattened vertebral
bodies, femoral head
deformity
− −
Alive (11 y) Alive (22 ½) Alive (32 y) Alive (15 y) Alive (15 y) Alive (10 y)
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described previously [7,22]. Sequencing reactions were performed
using the ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster
City, USA) as recommended by the manufacturer. The nomenclature
of the new GLB1 gene genetic lesions is as designed previously [23].
The GLB1 mutations were conﬁrmed in patients' and their relatives’
DNA. Informed consent for genetic tests was obtained for all analysed
patients included in the study.
2.4. Screening of new mutations and in silico analyses
The GLB1 gene of 60 normal control DNA samples was analysed by
sequencing analysis of the fragments containing the new missense
mutations identiﬁed. The PCR fragments were ampliﬁed by the
genomic primers reported earlier [7,22]. In addition, alignments of
GLB1 related proteins were performed by ClustalWmultiple sequence
alignment (http://align.genome.jp/) and the single amino acid sub-stitutions were also analysed by PolyPhen tool (http://genetics.bwh.
harvard.edu/pph/).
2.5. Mapping mutations onto structure of GLB-1 homology model
The structural effect of novel missense mutations on resulting
GLB1 enzymes was predicted by modelling the mutations onto the
three-dimensional structure of GLB1 based upon two crystal struc-
tures, one from Penicillium and one from Bacteroides (PDB codes 1XC6
and 3D3A, respectively). Amino acid substitutions corresponding to
mutant proteins were introduced into the predicted wild type
structure in the molecular graphics program O. Amino acid side
chain rotamers for the substitutions were chosen to minimise steric
clashes. The resulting three-dimensional model of the mutant
proteins was energy minimised in the program CNS. Molecular
ﬁgures were prepared with the program Molscript (http://www.
avatar.se/molscript/doc/index.html).
Table 2
Main clinical and instrumental data of Morquio B patients here reported.
Patient 22 23 24 25
Age (years) 46 42 24 36
Ethnic origin Caucasian Caucasian Caucasian Caucasian
Sex F M M M
Age at diagnosis 36 y 32 y 13 y and 9 m 10 y
GLB1 (% of control activity)⁎ 9.6 FB 10.4 FB 3.9 FB 3 FB
Parental consanguinity Yes (sister of 23) Yes (brother of 22) No No
Height (cm) at present 151 140 156.5 139
Weight (kg) at present 56 47 53 39
Spondyloepiphyseal dysplasia Yes Yes Yes Yes
Chest deformity Yes Yes Yes Yes
Hearing loss No No No Neurosensorial only in the left ear
Corneal clouding Very mild Very mild + −
Coxa valga Very mild Yes No (right hip replacement April 2009)
bilateral hip dysplasia
Mild
Odontoid hypoplasia No No No Yes and c2 c3 spondylolistesis
Hepato-splenomegaly No No No No
Cardiac involvement (left ventricular
hypertrophy/valvular heart disease)
Mild aortic reﬂux Mild aortic reﬂux Minimal aortic insufﬁciency Aortic valve insufﬁciency, mild mitral and tricuspid
regurgitation. Aortic substitution in 2007
Legend: F=female; M=male; −=not available data; no=normal; y=years; m=months. FB=on ﬁbroblasts.
⁎ Standard deviations generate conﬁdence limits less than 1% for all values.
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3.1. Phenotype–genotype correlations
The study includes 21 GM1 gangliosidosis patients of whom 14
presented with the infantile form of the disease and 6 patients can be
classiﬁed as juvenile (Tables 1 and 2). Due to her ambivalent mani-
festations, patient 15 was assigned as suffering from an infantile/
juvenile GM1 gangliosidosis phenotype (Table 1, part II). In addition, 4
Morquio B patients are described (Table 2). The lysosomal neuramin-Table 3
Molecular analyses of the 25 patients here reported.
Patient Phenotype Nucleotide change Mutations
1 Infantile GM1 c.442CNT/c.202CNT p.R148C/p.R
2 Infantile GM1 c.1736GNA/c.1736GNA p.G579D/p.G
3 Infantile GM1 c.1736GNA/c.1736GNA p.G579D/p.G
4 Infantile GM1 c.443GNA/c.1480 -2aNg p.R148H
5 Infantile GM1 c.1051CNT/c.1051CNT p.R351X/p.R
6 Infantile GM1 c.1069delT/c.1309 delA
7 Infantile GM1 c.481TNG/c.841CNT p.W161G/p
8 Infantile GM1 c.1040ANG/c.1040ANG p.Y347C/p.Y
9 Infantile GM1 c.994GNA/c.994GNA p.D332N/p.D
10 Infantile GM1 c.1321ANG/c.1445GNA p. D441N/p
11 Infantile GM1 c.275GNA/c.75+2dupT p.W92X
12 Infantile GM1 c.425_428del/c.841CNT p.H281Y
13 Infantile GM1 c.206TNC/c.1728GNA p.L69P/W57
14 Infantile GM1 c.1303 delC/c.1303 delC
15 Infantile/Juvenile GM1 c.1733 ANG/c.1733 ANG p.K578R/p.K
16 Juvenile GM1 c.152TNA/c.602GNA/ p.I51N/p. R2
17 Juvenile GM1 c.572GNA/c.1051CNT p.S191N/p.R
18 Juvenile GM1 c.602GNA/c.1728GNA p.R201H/p.W
19 Juvenile GM1 c.152TNA/c.602GNA p.I51N/p.R2
20 Juvenile GM1 c.1313GNA/c.1313GNA p.G438E/p.G
21 Juvenile GM1 c.275GNA/c.1325GNA p.W92X/R4
22 MorquioB c.851-852TGNCT/c.851-852TGNCT p.W273L/p.
23 MorquioB c.851-852TGNCT/c.851-852TGNCT p.W273L/p.
24 MorquioB c.851-852TGNCT/c.1480 -2aNg p.W273L
25 MorquioB c.1321ANG /c.851-852TGNCT p.D441N/p.W
Legend: (+/−)=heterozygous level; (+/+)=homozygous level. ref.= references. Bold t
⁎ Such polymorphism is present in cis with the p.R68W mutation.idase (NEU1) enzyme activity, assayed in leukocytes, was within the
normal range in all patients.
Psychomotordelayandhypotonia are themain symptomspresented
at the onset of the infantile and juvenile GM1 gangliosidosis forms.
Dysostosismultiplex andwhitematter alterationswere also detected in
most patients. GM1 gangliosidosis infantile patients also frequently
showed macrocephaly, but microcephaly can also be present at birth
(see patient 6, Table 1, part I). The clinical pictures of the 4Morquio type
B patients here reported, summarised in Table 2, showed the classic
phenotypes of the disease. It is worth to point out that, in patient 25, theOther genetic alterations Mutation ref. Polymorphism ref.
68W c.325CNT (p.R109W) (+/−)⁎ [27/7] [This work]
579D [22]
579D [22]
[This work/22]
351X c.325CNT (p.R109W) (+/+) [35] [This work]
c.1824GNC (p.L608L) (+/−) [This work/27
]
[This work]
H281Y c.29CNT (+/−),
c.858CNT (p.T286T) (+/−)
[This work/37] [38, This work]
347C c.792+10gNt (+/−) [39] [This work]
332N [29]
.R482H [39]/[40]
[This work/41]
c.29CNT (p.L10P) (+/−),
c.34CNT (p.L12L) (+/−),
c.858CNT (p.T286T) (+/−)
[This work/37] [38, This work]
6X c.29CNT (p.L10P) (+/−),
c.1594ANG (p.S532G) (+/−)
[This work/42] [29,38]
[This work]
578R [24]
01H [This work/43]
351X c.325CNT-(p.R109W) (+/−) [This work/35] [This work]
576X [42,43]
01H [This work, 43]
438E c.29CNT (p.L10P) (+/−) [35] [38]
42Q c.1233+8TNC (+/−),
c.1594ANG (p.S532G) (+/−)
[This work/2] [27,29]
W273L [40]
W273L [40]
[40]/[22]
273L [44]/[40]
ext indicates new genetic and protein changes.
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calciﬁed valvewith reduced oriﬁce and systolic turbulent ﬂow) resulted
in valve replacement (Table 2). Before surgery he also presented mild
mitral and tricuspid regurgitation. Pulmonary valve was normal.
The clinical assessments of three relevant cases (patients 1, 15 and
20, Table 1, part I and II) are given in more detail (Materials and
methods section) due to the complex correlation between their
phenotypes and molecular analyses.
Remarkably, patient 1 presented with mild neurological involve-
ment and no feeding problems until 1 year, that is atypical for an
infantile GM1 gangliosidosis patient. Patients 15 and 20 showed late-
onset GM1 gangliosidosis manifestations (the onset of symptoms and
the relatively old age of patient 15 at present, and the neurological
involvement of patient 20) coupled with GLB1 mutations previously
correlated to the infantile GM1 gangliosidosis and Morquio B pheno-
types, respectively [25,26].
Two prenatal diagnoses were performed based on the biochemical
andmolecular characterisationof patient5 andherparents. The foetuses
were both not affected, but the ﬁrst one was miscarried after the
prenatal sampling.
3.2. Molecular characterisation and in silico analyses
The patients’ GLB1 gene coding regions and the correspondent
exon/intron boundaries were ampliﬁed and directly sequenced onFig. 1. GLB1 sequence alignments between species. Family 35 glycosyl hydrolases and related
p.L69P, p.R109W, p.R148H, p.W161G, and p.S191N) identiﬁed in GM1 gangliosidosis patien
(:) very high homology; (.) high homology. (A) p.I51 and p.L69 amino acids. (B) p.R109both strands. The mutations identiﬁed were conﬁrmed in the parents’
genomic DNA. The p.K578R mutation, identiﬁed in patient 15, was
previously associated with the infantile phenotype [24]. In patient 20,
the p.G438E mutation, previously described in Morquio B patients
and type III GM1 gangliosidosis, both at a homozygous level [25,26],
was found. In patient 1, the new complex allele pR68W/p.R109W, in
combinationwith the known c.442CNT (p.R148C) [28], was found (see
Table 3).
A summary of the 27 mutations identiﬁed (18 known and 9 new)
in the GLB1 enzyme of the 25 patients here reported is shown
in Table 3. New genetic lesions include ﬁve amino acid substitutions
(p.I51N, p.L69P, p.R148H, p.W161G, and p.S191N), three small deletions
(c.425_428del, c.1069delT, and c.1303delC) and onenonsensemutation
(p.W92X).
A possible benign polymorphic nature of each new nucleotide
variants above mentioned was excluded by sequencing analysis of the
GLB1 exons containing the aforementioned mutated nucleotides in
120 control alleles. The presence of these amino acid substitutions
in less than 1% of normal alleles screened suggested that they are
not benign substitutions. In addition, sequence alignments of GLB1
related proteins (glycosyl hydrolase family 35) indicated that the
p.I51, p.L69, and p.W161 amino acids are highly conserved across
species, the p.R148 is quite conserved, while the p.S191 amino acid is
dispersed among species (Fig. 1). Polyphen analysis conﬁrmed the
data of ClustalW alignments (data not shown). However, a carefulproteins were aligned in the regions surrounding the new amino acid changes (p.I51N,
ts. Both aligned amino acids are indicated by squares. (*) Total sequence homology;
amino acid. (C) p.R148 and p.W161 amino acids. (D) p.S191 amino acid.
Fig. 2. Structural model of representative human GLB1 three-dimensional protein.
Homology model of human GLB1 based upon two crystal structures, one from
Penicillium and one from Bacteriodes, is presented. The structure was plotted and
the amino acid substitutions p.I51N, p.R68W, p.L69P, p.R109W, p.R148H, p.W161G, and
p.S191N were highlighted in the molecular graphic. The selected amino acids are in
yellow and the galactose ligand inwhite, with the protein painted fromNH2- starting to
COOH- terminal with blue to red colours.
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tion of this amino acid in mammalian (mouse), fungi (Aspergillus),
proteobacteria (the Gram – Xanthomonas manihotis) and in the
Gram+Bacillus circulans, while the complete loss of homology re-
sulted from alignments with the Gram+Actinobacterium (Arthro-
bacter) and with plants (Fig. 1).
In addition we identiﬁed four new nucleotide variants
[c.325CNT (p.R109W), c.1824GNC (p.L608L), c.858CNT (p.T286T),
and c.792+10gNt] with a predicted polymorphic nature due to
their presence in combination with two known mutations or with
here conﬁrmed to be pathogenetic alterations detected in the
correspondent patients’ GLB1 genes. The p.R109W amino acid
substitution, the only one involved in a missense change, was not
found in 180 control alleles. In contrast, in silico analyses (both
Polyphen and ClustalW alignments) predicted a polymorphic
nature with conﬁdent assignment (see Fig. 1). In addition patients
5 and 17 (Table 1, parts I and II) also presented this amino acid
substitution, and from genetic analysis on their families the p.
R109W was proven to be in association (in cis) with the known p.
R351X stop mutation in both cases.Table 4
Prediction of consequences of novel missense amino acid changes using the 3Dmodel based
and 3D3A, respectively).
Mutation Protein position Modelling analysis prediction
p.I51N Hydrophobic pocket The replacement of a nonpolar residue in a hydrop
p.L69P Core The change of a buried nonpolar residue of a helix
p.R148H Core The p.R148 is a completely buried residue, and rep
p.W161G Core The p.W161 is a large hydrophobic residue located
in the core of the protein.
p.S191N Surface The p.S191 amino acid is exposed in a turn, and it
the protein, giving evidence of a mildly compromis
p.R68W Core The replacement of a buried Arg by a large aromat
to a seriously affected protein.
p.R109W Surface This amino acid change, detected in cis with the se
(patients 5 and 17, Table 1), is a surface exposed c
accommodated into the protein structure but it ma3.3. Three-dimensional analyses
To further explain the effects of the new amino acid changes, we
looked at the protein structure on the molecular predicted graphic of
human GLB1 (Fig. 2).
As shown in Table 4, each mutation is predicted to inﬂuence the
protein structure in different ways, from changes in polarity to
packing defects and changes in aggregation proneness.
4. Discussion
Themolecular bases of the diseases can be related (i) to the kinetic
and processing of mutated GLB1, (ii) to the role of both GLB1 gene
products, GLB1 and EBP, and (iii) to the interactions of these proteins
within their complexes inside lysosomes and on the cell surface,
respectively [19,20].
Of the 27 different genetic lesions identiﬁed in our patients’
cohort 9 were new, conﬁrming the high genetic heterogeneity of
GLB1 gene.
The common mutation p.R201H was identiﬁed in 3 Juvenile
patients, and the p.W273L in at least one allele of Morquio B patients
(see Table 3). The p.G579D was found in 2 unrelated patients and it
was previously reported in Italian infantile patients [22,27].
The p.I51N was detected in two juvenile patients in combination
with the p. R201H. These patients, although consanguinity was not
referred, are both from a small village in Southern Italy.
The new nonsense mutation p.W92X was identiﬁed in two un-
related patients with different phenotype (see Table 3).
The discussion of the cases at a clinical and genetic level underlines
that unequivocal genotype phenotype correlations are difﬁcult to
be drawn. In particular, patient 21 is a compound heterozygous for the
p.W92X and p.R442Q mutations with about 5% of residual GLB1
activity. The p.R442Q change was previously detected in a compound
heterozygous Italian patient with an adult phenotype [28]. Expression
studies demonstrated that the p.R442Q showed residual GLB1
enzyme activity in contrast with a total absence of GLB1 activity in
the in vitro expression system of the p.T329A mutation. In this adult
patient no additional genetic variants predicted to have a modulating
effects were detected [28: personal data]. Patient 21 (10 years old)
recently showed a severe CNS neurological worsening, thus being
classiﬁed as affected by the juvenile form. Her clinical outcome is
quite different from the reported adult patient [28], who shares
with her the p.R442Q mutant allele but who presents a very mild
CNS involvement at the age of 27 years (last referred examination
before starting therapywithMiglustat). A known polymorphic variant
(p.S532G) [29], that leads to a complex allele carrying the p.R442Q
and p.S532G variants, was identiﬁed in the GLB1 gene of patient 21. An
inﬂuence of this combination in determining residual enzyme activity
and thus phenotype might be hypothesised. We would like to pointon the beta-galactosidase related protein of Penicillium and Bacteroides (PDB codes 1XC6
hobic pocket into a polar residue is likely to adversely affect the fold of the protein.
into a proline will introduce a kink in the helix.
lacing it with His will introduce a defect into the hydrophobic core of the protein.
in the core of the protein. Replacement with glycine will lead to a signiﬁcant defect
appears that replacement with the similar Asn residue should be accommodated by
ed protein.
ic Trp would signiﬁcantly affect the packing of the core of the molecule, giving rise
vere p.R68W mutation (patient 1, Table 1), and with the stop mutation p.R351X
harged residue change into a large aromatic residue. This is likely to be
kes the protein more aggregation prone.
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play a role in determining phenotypes, especially when considering
otherwise ambivalent genotype/phenotype correlations.
Patient 1 showed a complex GLB1 allele carrying two genetic
variants leading to p.R68W in cis with the p.R109W amino acid change
and in trans with the known c.442CNT (p.R148C) mutation. Previously
developed expression systems carrying the p.R68W and p.R148C
mutations showed no GLB1 enzyme activity [7,27], thus correlating
these mutations to the infantile phenotype. However, this patient
was not referred to show psychomotor delay until 1 year of age.
Genotype/phenotype correlations were investigated further by Poly-
phen and ClustalW tools and by structure analysis. All in silico analyses
indicated that the p.R68W is a severe mutation located in an extremely
conservedGLB1 region, affecting the packingof the core of themolecule.
The amino acid change p.R109W, that is positioned in cis with the p.
R68Wmutation, resultedpolymorphic frombothperformedalignments
(ClustalW output is shown in Fig. 1). However, mutation screening by
sequencing analyses failed to ﬁnd the correspondent genetic lesion in
about 90 control DNAs (180 alleles).
Mutation of a surface exposed residue from arginine to
tryptophan would result in much more hydrophobic surface on
the molecule, which may lead to aggregation of the protein.
Protein interfaces are enriched in aromatic residues like trypto-
phan, 21% vs. 8% in non-interface surface residues [30]. The most
common pairing of residues in protein–protein interfaces involves
interactions between hydrophobic residues, especially the bulky
aromatic residues [31]. The amino acids Trp, Met, and Phe are
important for protein–protein interactions [32]. Thus, the intro-
duction of a large aromatic residue like a tryptophan makes the
protein more likely to interact with other proteins and make it
more likely to aggregate.
To assess the possibility that this amino acid change (p.R109W)
has a modulating role, the maturation of the GLB1 precursor may be
considered. Such maturation requires the association of GLB1 with
protective protein/cathepsin A (PPCA) [29]. The GLB1–PPCA complex
(680 kDa), made up of four GLB1 and eight PPCA, is the major
oligomeric form of GLB1 inside lysosomes [20]. The GLB1 enzyme can
also form a lysosomal complex with PPCA, NEU1, and N-acetylamino-
galacto-6-sulfate sulfatase [20,33]. Thus, considering the relatively mild
phenotype of patient 1 and his particular genetic assessment, a
hypothetic role in assisting the aggregative processes of deﬁcient
GLB1 could be considered for the p.R109W amino acid change.
At least in the patients with Italian origin (patients 5 and 17), the
relatively high occurrence of the p.R109W in the GM1 gangliosidosis
patients can be linked to the p.R351X allele; thus a founder effect that
gave rise to the spread of the two combined amino acid changes in
Southern Italy can be proposed.
Sequence and structural data and in silico analyses also shed light
on the p.S191N mutation. In silico analyses suggest the p.S191 amino
acid to be positioned in a non-fully conserved GLB1 region. Such a
mutation, detected in combination with a stop change, was detected
in a juvenile patient showing relatively high GLB1 residual activity
(63 nmol/mg/h n.v. 117–408 nmol/mg/h) (patient 17, Tables 1, part II,
and 3). The patient's late-onset phenotype, the high residual enzyme
activity and the absence of the mutation in 110 alleles from the
normal population indicate that such genetic alteration is a mutation
and that it can be linked to late-onset phenotypes.
Among all the reported mutations, the p.K578R, detected at a
homozygous level in an alive 3 and 1/2 year female (patient 15, Tables 1,
part I, and 3), was previously described in the infantile phenotype [24].
GLB1 assay showed partial residual enzyme activity, but the course of
the disease in this patient was rapid, with psychomotor regression by
1 year of age. However, the disease onset and the relatively prolonged
survival do notmeet the criteria of the infantile phenotype. Thepatient's
phenotype is less severe than previously described for a GLB1 infantile
genotype, and although we cannot experimentally exclude a possiblecontribution of the associated triple X syndrome, her clinical course
does not seem to be further worsened.
Patient 20 was homozygous for the c.1313GNA (p.G438E) muta-
tion, previously described at a homozygous level both in Morquio B
and in GM1 gangliosidosis type III patients [25,26]. Our patient shows
some features of skeletal dysplasia typical of Morquio syndrome,
i.e., thoracic deformity and short stature but no ligamentous laxity.
Indeed, she showed neurological involvement including dystonia and
anarthria. Miglustat treatment, undertaken in this patient for about
24 months, did not stop the general clinical worsening, although
we underline the short period of therapy.
The clinical, biochemical and genetic analyses of patients 15 and 20
ﬁrmly suggest the complexity in determining genotype/phenotype
correlations and in predicting the clinical course of late-onset GM1
gangliosidosis/Morquio B patients. Indeed, mutations such as the p.
G438E, p.R201H, and p.S191N may be associated with late-onset
phenotypes (Morquio B, juvenile or adult GM1 gangliosidosis).
Clinical assessment of our cohort also suggests that some symp-
toms such as severe skeletal dysplasia and facial dysmorphisms,
strictly related to Morquio B syndrome and infantile GM1 gang-
liosidosis [34], can be present in late-onset GM1 gangliosidosis.
Complicating eventual genotype phenotype correlations, the same
genetic assessment (p.I51N/p.R201H)was present in two patients (16
and 19), who exhibit quite different symptoms. In particular, patient
19 presents severe skeletal involvement and corneal opacity, that are
not shared by patient 16.
Patients here reported with the Morquio B phenotype showed
classical features of the disease, i.e., skeletal involvement, normal
neurological development and keratan sulfate urinary excretion [17]. It
is known that cell lines frompatientswithMorquio B also showa reduced
capacity to assemble elastic ﬁbers, linked to alterations in EBP [20,35].
Thus, impaired elastogenesis with skeletal-connective tissue alterations,
typical of Morquio syndrome, and cardiac involvement, can be related to
bothGLB1 andEBP alterations [22]. Patient 25's clinical picture resembled
that of Morquio B, particularly in view of the severe impairment of
cardiac function that necessitated surgery with aortic valve replacement.
5. Conclusions
The tertiary structure of humanGLB1hasnot been resolved andonly a
previoushomologymodel of humanGLB1wasderived fromthe structure
of the Bacteroides thetaiotaomicron GLB1 protein has been reported
[21]. Here we have used two structures of GLB1 from Penicillium and
Bacteroides to produce an improved homology model of human GLB1.
Three-dimensional analysis and in silico outputs of mutated GLB1
proteins are helpful tools in deﬁning patients’ phenotypes. However, a
clear-cut phenotype classiﬁcation between GM1 types I, II, III and
Morquio B can be difﬁcult. The considerations raised from the clinical
and genetic assessment of our patients’ cohort together with the
description of a neurological Morquio type B form [6], and with
previous evaluations on the convergence between the different forms
of GM1 gangliosidosis and between GM1 gangliosidosis and Morquio
B [7,22,25,34,36], warn physicians about the complications of deﬁning
disease severity in each case, and therefore of recommending any
treatment that may be available. Polymorphisms could also play
interesting roles on resulting enzyme activities and/or phenotypes.
At a glance, a continuum of phenotypes can be remarked in all
carefully examined patients in whomGLB1 enzyme activity is deﬁcient.
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